PAVmed
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 107
- Market Cap
- -
- Introduction
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. The company's products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. PAVmed was founded on June 26, 2014 and is headquartered in New York, NY.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System
- Conditions
- Chronic Kidney Disease stage4Chronic Kidney Disease stage3Poor Vascular AccessChronic Kidney Disease Stage 5
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- PAVmed Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06037265
- Locations
- 🇨🇴
Cediul, Barranquilla, Atlantico, Colombia
🇨🇴Sabbag Radiologos, Barranquilla, Atlantico, Colombia
🇨🇴Cirulaser Andes, Bogotá, Bogota, Colombia
PAVmed CarpX Device Clinical Study
- Conditions
- Carpal Tunnel Syndrome
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- PAVmed Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03747510
- Locations
- 🇳🇿
Christchurch Hospital, Christchurch, New Zealand
News
Lucid Diagnostics Expands EsoGuard Access Through Concierge Medicine and Secures First Commercial Insurance Coverage
Lucid Diagnostics has partnered with LEAA Health to offer its EsoGuard Esophageal DNA Test to concierge medicine patients on a cash-pay basis, targeting the growing $10.9 billion concierge medicine market projected by 2032.
EsoGuard Esophageal DNA Test Demonstrates High Clinical Utility in Detecting Barrett's Esophagus
A new study demonstrates the clinical utility of Lucid Diagnostics' EsoGuard test for detecting Barrett's Esophagus.